02687nas a2200409 4500000000100000008004100001260001300042653001000055653001600065653001000081653002800091653003000119653003000149653001100179653001100190653002300201653001200224653002000236653000900256653003100265653002700296653001600323653001400339653002800353653001500381653001700396653001700413100001700430700001100447700001100458700001500469245010900484300001100593490000700604520165200611022001402263 1994 d c1994 Aug10aAdult10aAge Factors10aChina10aCross-Sectional Studies10aDrug Therapy, Combination10aEye Infections, Bacterial10aFemale10aHumans10aLeprostatic Agents10aleprosy10aLogistic Models10aMale10aMedically Underserved Area10aMeta-Analysis as Topic10aMiddle Aged10aMorbidity10aPopulation Surveillance10aPrevalence10aRisk Factors10aTime Factors1 aCourtright P1 aHu L F1 aLi H Y1 aLewallen S00aMultidrug therapy and eye disease in leprosy: a cross-sectional study in the People's Republic of China. a835-420 v233 a

BACKGROUND: Factors associated with leprosy-related eye disease in a multidrug therapy (MDT) treated population in China were assessed to determine if status prior to inclusion in the MDT programme (newly diagnosed leprosy patient or leprosy patient on prior dapsone monotherapy) contributed to the prevalence of ocular pathology.

METHODS: Trained leprosy paramedical workers in Sichuan Province examined 974 leprosy patients in a standardized fashion. Univariate analyses and multiple logistic regression were used to assess the contribution of demographic and clinical parameters to leprosy-related eye disease.

RESULTS: In both groups (prior dapsone and new MDT) leprosy-related eye disease was associated with a longer distance to leprosy health worker or health centre. Among patients with a history of prior dapsone monotherapy, age and duration on dapsone monotherapy were also associated with leprosy-related ocular morbidity. Among newly diagnosed leprosy patients the prevalence of ocular morbidity remained between 8% and 11% regardless of when the patient started MDT.

CONCLUSIONS: Our findings suggest that, even when case detection is good, ocular pathology will still occur in MDT treated leprosy patients. There remains an important role for health workers in the prevention of ocular morbidity. Our data also demonstrated that pooling of results from all patients (newly diagnosed and on prior dapsone monotherapy) in a leprosy control programme will likely give rise to inadequate estimates of risk of ocular disease due to variable clinical disease histories in these groups.

 a0300-5771